O	0	9	Epidermal	Epidermal	JJ	B-NP
O	10	16	growth	growth	NN	I-NP
O	17	23	factor	factor	NN	I-NP
O	24	27	and	and	CC	O
O	28	31	its	its	PRP$	B-NP
O	32	40	receptor	receptor	NN	I-NP
O	40	41	.	.	.	O

O	43	52	Epidermal	Epidermal	JJ	B-NP
O	53	59	growth	growth	NN	I-NP
O	60	66	factor	factor	NN	I-NP
O	67	68	(	(	(	O
O	68	71	EGF	EGF	NN	B-NP
O	71	72	)	)	)	O
O	73	78	binds	bind	VBZ	B-VP
O	79	83	with	with	IN	B-PP
O	84	88	high	high	JJ	B-NP
O	89	97	affinity	affinity	NN	I-NP
O	98	101	and	and	CC	I-NP
O	102	113	specificity	specificity	NN	I-NP
O	114	116	to	to	TO	B-PP
O	117	118	a	a	DT	B-NP
O	119	125	single	single	JJ	I-NP
O	126	130	site	site	NN	I-NP
O	131	133	on	on	IN	B-PP
O	134	137	the	the	DT	B-NP
O	138	146	external	external	JJ	I-NP
O	147	153	domain	domain	NN	I-NP
O	154	156	of	of	IN	B-PP
O	157	160	its	its	PRP$	B-NP
B-Cellular_component	161	174	transmembrane	transmembrane	JJ	I-NP
O	175	183	receptor	receptor	NN	I-NP
O	184	186	to	to	TO	B-VP
O	187	195	activate	activate	VB	I-VP
O	196	199	the	the	DT	B-NP
O	200	208	tyrosine	tyrosine	NN	I-NP
O	209	216	protein	protein	NN	I-NP
O	217	223	kinase	kinase	NN	I-NP
O	224	232	activity	activity	NN	I-NP
O	233	235	of	of	IN	B-PP
O	236	239	its	its	PRP$	B-NP
B-Organism_substance	240	251	cytoplasmic	cytoplasmic	JJ	I-NP
O	252	259	portion	portion	NN	I-NP
O	259	260	.	.	.	O

O	261	264	The	The	DT	B-NP
O	265	268	EGF	EGF	NN	I-NP
O	269	277	receptor	receptor	NN	I-NP
O	278	282	gene	gene	NN	I-NP
O	283	285	is	be	VBZ	B-VP
O	286	295	amplified	amplify	VBN	I-VP
O	296	299	and	and	CC	O
O	300	304	over	over	AFX	B-NP
O	304	305	-	-	HYPH	I-NP
O	305	314	expressed	express	VBN	B-VP
O	315	317	in	in	IN	B-PP
O	318	325	several	several	JJ	B-NP
O	326	331	human	human	JJ	I-NP
B-Cancer	332	338	tumors	tumor	NNS	I-NP
O	338	339	,	,	,	O
O	340	350	suggesting	suggest	VBG	B-VP
O	351	355	that	that	IN	B-SBAR
O	356	365	increased	increase	VBN	B-NP
O	366	380	concentrations	concentration	NNS	I-NP
O	381	383	of	of	IN	B-PP
O	384	387	the	the	DT	B-NP
O	388	393	proto	proto	AFX	I-NP
O	393	394	-	-	HYPH	I-NP
O	394	402	oncogene	oncogene	NN	I-NP
O	403	408	leads	lead	VBZ	B-VP
O	409	411	to	to	TO	B-PP
O	412	424	constitutive	constitutive	JJ	B-NP
O	425	433	activity	activity	NN	I-NP
O	434	441	similar	similar	JJ	B-ADJP
O	442	444	to	to	TO	B-PP
O	445	449	that	that	DT	B-NP
O	450	454	seen	see	VBN	B-VP
O	455	459	with	with	IN	B-PP
O	460	468	oncogene	oncogene	NN	B-NP
O	469	472	erb	erb	NN	I-NP
O	473	474	B	B	NN	I-NP
O	474	475	.	.	.	O

O	476	485	Synthesis	Synthesis	NN	B-NP
O	486	489	and	and	CC	I-NP
O	490	501	degradation	degradation	NN	I-NP
O	502	504	of	of	IN	B-PP
O	505	508	the	the	DT	B-NP
O	509	512	EGF	EGF	NN	I-NP
O	513	521	receptor	receptor	NN	I-NP
O	522	525	are	be	VBP	B-VP
O	526	535	regulated	regulate	VBN	I-VP
O	535	536	,	,	,	O
O	537	539	in	in	IN	B-PP
O	540	548	addition	addition	NN	B-NP
O	548	549	,	,	,	O
O	550	558	covalent	covalent	JJ	B-NP
O	559	571	modification	modification	NN	I-NP
O	572	574	by	by	IN	B-PP
O	575	590	phosphorylation	phosphorylation	NN	B-NP
O	591	600	regulates	regulate	VBZ	B-VP
O	601	609	activity	activity	NN	B-NP
O	610	612	of	of	IN	B-PP
O	613	616	the	the	DT	B-NP
O	617	625	receptor	receptor	NN	I-NP
O	626	633	protein	protein	NN	I-NP
O	633	634	.	.	.	O

O	635	649	Intramolecular	Intramolecular	JJ	B-NP
O	650	654	self	self	AFX	I-NP
O	654	655	-	-	HYPH	I-NP
O	655	670	phosphorylation	phosphorylation	NN	I-NP
O	671	673	of	of	IN	B-PP
O	674	681	Tyr1173	Tyr1173	NN	B-NP
O	682	689	removes	remove	VBZ	B-VP
O	690	691	a	a	DT	B-NP
O	692	703	competitive	competitive	JJ	I-NP
O	704	714	inhibitory	inhibitory	JJ	I-NP
O	715	725	constraint	constraint	NN	I-NP
O	726	728	to	to	TO	B-VP
O	729	736	enhance	enhance	VB	I-VP
O	737	752	phosphorylation	phosphorylation	NN	B-NP
O	753	755	of	of	IN	B-PP
O	756	766	substrates	substrate	NNS	B-NP
O	766	767	.	.	.	O

O	768	783	Phosphorylation	Phosphorylation	NN	B-NP
O	784	786	of	of	IN	B-PP
O	787	793	Thr654	Thr654	NN	B-NP
O	794	796	by	by	IN	B-PP
O	797	804	protein	protein	NN	B-NP
O	805	811	kinase	kinase	NN	I-NP
O	812	813	C	C	NN	I-NP
O	814	823	decreases	decrease	VBZ	B-VP
O	824	828	high	high	JJ	B-NP
O	829	837	affinity	affinity	NN	I-NP
O	838	841	EGF	EGF	NN	I-NP
O	842	849	binding	binding	NN	I-NP
O	850	853	and	and	CC	I-NP
O	854	857	EGF	EGF	NN	I-NP
O	857	858	-	-	HYPH	O
O	858	868	stimulated	stimulate	VBN	B-NP
O	869	877	tyrosine	tyrosine	NN	I-NP
O	878	885	protein	protein	NN	I-NP
O	886	892	kinase	kinase	NN	I-NP
O	893	901	activity	activity	NN	I-NP
O	901	902	,	,	,	O
O	903	912	providing	provide	VBG	B-VP
O	913	914	a	a	DT	B-NP
O	915	924	mechanism	mechanism	NN	I-NP
O	925	928	for	for	IN	B-PP
O	929	941	heterologous	heterologous	JJ	B-NP
O	942	952	regulation	regulation	NN	I-NP
O	953	955	of	of	IN	B-PP
O	956	959	the	the	DT	B-NP
O	960	963	EGF	EGF	NN	I-NP
O	964	972	receptor	receptor	NN	I-NP
O	973	975	by	by	IN	B-PP
B-Cancer	976	981	tumor	tumor	NN	B-NP
O	982	991	promoters	promoter	NNS	I-NP
O	992	995	and	and	CC	O
O	996	1001	other	other	JJ	B-NP
O	1002	1008	ligand	ligand	NN	I-NP
O	1009	1010	X	X	NN	I-NP
O	1011	1019	receptor	receptor	NN	I-NP
O	1020	1029	complexes	complex	NNS	I-NP
O	1029	1030	.	.	.	O

O	1031	1040	Extensive	Extensive	JJ	B-NP
O	1041	1051	regulation	regulation	NN	I-NP
O	1052	1063	contributes	contribute	VBZ	B-VP
O	1064	1066	to	to	TO	B-PP
O	1067	1073	normal	normal	JJ	B-NP
O	1074	1080	growth	growth	NN	I-NP
O	1081	1088	control	control	NN	I-NP
O	1088	1089	,	,	,	O
O	1090	1100	abrogation	abrogation	NN	B-NP
O	1101	1103	of	of	IN	B-PP
O	1104	1114	regulatory	regulatory	JJ	B-NP
O	1115	1123	controls	control	NNS	I-NP
O	1124	1135	contributes	contribute	VBZ	B-VP
O	1136	1138	to	to	TO	B-PP
O	1139	1151	uncontrolled	uncontrolled	JJ	B-NP
O	1152	1158	growth	growth	NN	I-NP
O	1159	1161	as	as	IN	B-SBAR
O	1162	1166	seen	see	VBN	B-VP
O	1167	1171	with	with	IN	B-PP
O	1172	1175	erb	erb	NN	B-NP
O	1176	1177	B	B	NN	I-NP
O	1178	1192	transformation	transformation	NN	I-NP
O	1193	1196	and	and	CC	O
O	1197	1200	EGF	EGF	NN	B-NP
O	1201	1209	receptor	receptor	NN	I-NP
O	1210	1214	gene	gene	NN	I-NP
O	1215	1228	amplification	amplification	NN	I-NP
O	1229	1231	in	in	IN	B-PP
O	1232	1237	human	human	JJ	B-NP
B-Cancer	1238	1244	tumors	tumor	NNS	I-NP
O	1244	1245	.	.	.	O

